# spark-therapeutics

**Canonical:** https://apis.io/providers/spark-therapeutics/  
**Website:** https://www.gene.com/spark  
**APIs profiled:** 0

Spark Therapeutics is a Philadelphia-based gene therapy company founded in 2013 with roots at Children's Hospital of Philadelphia (CHOP). Spark developed Luxturna (voretigene neparvovec-rzyl), the first FDA-approved gene therapy for a genetic disease in the United States, approved in December 2017 for the treatment of inherited retinal disease caused by biallelic RPE65 mutations. Roche acquired Spark Therapeutics in December 2019 for approximately $4.3 billion, and Spark has since been integrated into the Roche Group, operating as a Genentech subsidiary. The original sparktx.com domain now redirects to gene.com/spark. Spark does not publish any public developer APIs, OpenAPI specifications, SDKs, or GitHub organization. As a pharmaceutical/biotech operating under Roche, Spark's public technical surface is limited to patient and prescriber information for Luxturna and adverse event reporting channels (FDA MedWatch and 1-855-SPARKTX).

## Kin Score — 6.7 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 6.7).

| Facet | Score |
|---|---|
| Discoverability | 44.4 |
| Contract Quality | 0.0 |
| Governance | 15.2 |
| Contract Governance | 15.2 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 21.3 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (2)

- **Spark Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC
- **Spark Therapeutics Vulnerability Disclosure** — Hackerone · security.txt · contact published

## Tags

Biotechnology, Pharmaceuticals, Gene Therapy, Rare Disease, Ophthalmology, Inherited Retinal Disease, Roche Subsidiary, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/spark-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.